NCT06126809 Causal Role of the Aperiodic Signal for Working Memory
| NCT ID | NCT06126809 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Florida State University |
| Condition | Executive Dysfunction |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-03-25 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-03-25 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Working memory (WM) is the ability to hold relevant information in mind in the absence of sensory input. The capacity for WM is a foundation for cognitive control and higher cognitive function more broadly. Previous research demonstrated that during the delay period of WM tasks, oscillatory electrical activity in the prefrontal cortex in the theta-frequency band (4-8 Hz) increased in amplitude. However, other groups found that the slope of the aperiodic signal in the brain was positively correlated with individual differences in WM capacity. Since low-frequency power and a steeper slope of the aperiodic signal are confounded in many analyses, it is not clear whether the slope of the aperiodic signal or the amplitude of low-frequency oscillations underlie WM capacity. With many studies investigating the causal role of theta oscillations in WM, the purpose of this project is to investigate the role of the aperiodic signal in WM performance.
Eligibility Criteria
Inclusion Criteria: * Between the ages of 18 and 35 * Able to provide informed consent * Normal or corrected-to-normal vision * Willing to comply with all study procedures and be available for the duration of the study * Ability to speak, read and understand English without a translator * Not color-blind Exclusion Criteria: * ADHD/ADD (currently under treatment) * Neurological disorder and conditions * Medical or neurological illness or treatment for a medical disorder that could interfere with study participation, e.g., unstable cardiac disease, HIV/AIDS, malignancy, liver or renal impairment * Prior brain surgery * Any brain devices/implants, including cochlear implants and aneurysm clips * History of traumatic brain injury * (For females) Pregnant * Anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study * Current use of medications know to produce specific EEG activity known to disrupt interpretations of the findings including but not limited to: benzodiazepines, antipsychotics, antiepileptics and central nervous system stimulants
Contact & Investigator
Justin Riddle, PhD
PRINCIPAL INVESTIGATOR
Florida State University
Frequently Asked Questions
Who can join the NCT06126809 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 35 Years, studying Executive Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06126809 currently recruiting?
Yes, NCT06126809 is actively recruiting participants. Contact the research team at jriddle@fsu.edu for enrollment information.
Where is the NCT06126809 trial being conducted?
This trial is being conducted at Tallahassee, United States.
Who is sponsoring the NCT06126809 clinical trial?
NCT06126809 is sponsored by Florida State University. The principal investigator is Justin Riddle, PhD at Florida State University. The trial plans to enroll 30 participants.